Providing meaningful survival benefit to hepatocellular carcinoma patients:combination therapy of future
作者机构：Department of Human and Molecular GeneticsMassey Cancer Center and VCU Institute of Molecular Medicine(VIMM)Virginia Commonwealth UniversityRichmondVAUSA
出 版 物：《Hepatobiliary Surgery and Nutrition》 (肝胆外科与营养（英文）)
年 卷 期：2022年第11卷第5期
页 面：779-781页
核心收录：
学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学]
基 金：supported in part by The National Cancer Institute(NCI)Grants(Nos.1R01CA230561-01A1,1R01CA240004-01 and 1R01CA244993-01) The National Institute of Diabetes and Digestive and Kidney Diseases(NIDDK)Grant(No.2R01DK107451-05)
摘 要：Hepatocellular carcinoma(HCC)is a highly fatal disease,the mortality of which runs parallel to its ***,viral hepatitis has been the major cause of HCC(1).Vaccine is available for hepatitis B virus(HBV)and a drug cocktail is effective in bringing down blood hepatitis C virus(HCV)level to *** successful application of mRNA vaccine for COVID-19,it is a matter of time before an effective vaccine for HCV is *** these positive advancements,the incidence of HCC is continuing to rise because of HCC development as a direct consequence of non-alcoholic steatohepatitis(NASH)caused by obesity(1).While viral hepatitis is waning in the Western countries,obesity is now a global problem,requiring impactful treatment regimen for HCC that can provide meaningful survival benefit.
维普期刊数据库